BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnson S, Taylor CM. What's new in haemolytic uraemic syndrome? Eur J Pediatr 2008;167:965-71. [PMID: 18575887 DOI: 10.1007/s00431-008-0745-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Abrera-Abeleda MA, Nishimura C, Frees K, Jones M, Maga T, Katz LM, Zhang Y, Smith RJ. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 2011;22:1551-9. [PMID: 21784901 DOI: 10.1681/ASN.2010080795] [Cited by in Crossref: 70] [Cited by in F6Publishing: 38] [Article Influence: 6.4] [Reference Citation Analysis]
2 Dini C, Islan GA, de Urraza PJ, Castro GR. Novel Biopolymer Matrices for Microencapsulation of Phages: Enhanced Protection Against Acidity and Protease Activity: Novel Biopolymer Matrices for Microencapsulation of Phages: Enhanced Protection …. Macromol Biosci 2012;12:1200-8. [DOI: 10.1002/mabi.201200109] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
3 Ferraris V, Acquier A, Ferraris JR, Vallejo G, Paz C, Mendez CF. Oxidative stress status during the acute phase of haemolytic uraemic syndrome. Nephrology Dialysis Transplantation 2011;26:858-64. [DOI: 10.1093/ndt/gfq511] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
4 Tomat D, Balagué C, Casabonne C, Verdini R, Quiberoni A. Resistance of foodborne pathogen coliphages to thermal and physicochemical treatments applied in food manufacture. Innovative Food Science & Emerging Technologies 2015;30:184-91. [DOI: 10.1016/j.ifset.2015.04.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
5 Pérez-Luna VH, González-Reynoso O. Encapsulation of Biological Agents in Hydrogels for Therapeutic Applications. Gels 2018;4:E61. [PMID: 30674837 DOI: 10.3390/gels4030061] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
6 Cayci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol 2012;27:2327-31. [PMID: 22903728 DOI: 10.1007/s00467-012-2283-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
7 Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. [PMID: 21902819 DOI: 10.1186/1750-1172-6-60] [Cited by in Crossref: 375] [Cited by in F6Publishing: 304] [Article Influence: 34.1] [Reference Citation Analysis]
8 Zipfel PF. Complement and immune defense: from innate immunity to human diseases. Immunol Lett 2009;126:1-7. [PMID: 19616581 DOI: 10.1016/j.imlet.2009.07.005] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 6.3] [Reference Citation Analysis]
9 Chen YY, Han SS, Cao Y, Yu XJ, Zhu L, Luo JC, Song WC, Yu F, Mao YH, Zhao MH. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study. Clin Immunol 2021;229:108794. [PMID: 34245915 DOI: 10.1016/j.clim.2021.108794] [Reference Citation Analysis]
10 Reid VL, Mullan A, Erwig LP. Rapid recovery of membrane cofactor protein (MCP; CD46) associated atypical haemolytic uraemic syndrome with plasma exchange. BMJ Case Rep 2013;2013:bcr2013200980. [PMID: 24005975 DOI: 10.1136/bcr-2013-200980] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
11 Tomat D, Soazo M, Verdini R, Casabonne C, Aquili V, Balagué C, Quiberoni A. Evaluation of an WPC edible film added with a cocktail of six lytic phages against foodborne pathogens such as enteropathogenic and Shigatoxigenic Escherichia coli. LWT 2019;113:108316. [DOI: 10.1016/j.lwt.2019.108316] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
12 Webster K, Schnitzler E. Hemolytic uremic syndrome. Handb Clin Neurol 2014;120:1113-23. [PMID: 24365375 DOI: 10.1016/B978-0-7020-4087-0.00075-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
13 Davin JC, van de Kar NC. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6:171-85. [PMID: 26288712 DOI: 10.1177/2040620715577613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
14 Dini C, Bolla PA, de Urraza PJ. Treatment of in vitro enterohemorrhagic Escherichia coli infection using phage and probiotics. J Appl Microbiol 2016;121:78-88. [PMID: 26969848 DOI: 10.1111/jam.13124] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
15 Dini C, De Urraza PJ. Isolation and selection of coliphages as potential biocontrol agents of enterohemorrhagic and Shiga toxin-producing E. coli (EHEC and STEC) in cattle. J Appl Microbiol 2010;109:873-87. [PMID: 20353429 DOI: 10.1111/j.1365-2672.2010.04714.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]